New Approaches to the Pharmacological Treatment of Anxiety and Depression

  • Y. D. Lapierre


Psychopharmacological advances in the last decade have contributed to the treatment of anxiety and depression in a number of ways. These developments have modified the conceptual framework of the biological understanding of these conditions and have led to a differentiation of subgroups of patients within the broad diagnostic categories of anxiety and depression. These more specific sub-categories are based for the most part on differences in treatment response. Psychopharmacology has also led to changes in nosology, the development of laboratory diagnostic tools, methods of response prediction and to the use of more neurochemically specific therapeutic agents. In addition to these advances, drug developments have resulted in the use of chemicals which, while maintaining initial therapeutic objectives, have fewer of the adverse effects which limited the use of the earlier compounds. In this chapter, an attempt will be made to review these developments of the last few years.


Anxiety Disorder Generalize Anxiety Disorder Panic Disorder Panic Attack Anxiolytic Effect 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Akindele, M. O., Evans, J. I., & Oswald, I. (1970). Monoamine oxidase inhibitors, sleep and mood. Electroencephalogram and Clinical Neurophysiology, 29, 47–56.CrossRefGoogle Scholar
  2. Asberg, M., Bertilsson, K., & Tuck, D. (1972). Indolamine metabolites in the cerebrospinal fluid of depressed patients before and during treatment with nortriptyline. Clinical and Pharmacological Therapy, 14, 277–286.Google Scholar
  3. Asberg, M., Thoren, P., & Traskman, L. (1976). Serotonin depression: A biochemical subgroup within the affective disorders? Science, 191, 478–480.PubMedCrossRefGoogle Scholar
  4. Belmaker, R. H. (1981). Receptors, adenylate cyclase, depression, and lithium. Biological Psychiatry, 16, 333–350.PubMedGoogle Scholar
  5. Bond, A. J., & Lader, M. H. (1981). Comparative effects of diazepam and buspirone on subjective feelings, psychological tests and the EEG. International Pharmacopsychiatry, 16, 212–220.PubMedGoogle Scholar
  6. Braestrup, C., Nielsen, M., & Olsen, C. E. (1980). Urinary and brain carboline-3-carboxylates as potent inhibitors of brain benzodiazepine receptors. Proceedings of the National Academy of Science U.S.A., 77, 2288–2292.CrossRefGoogle Scholar
  7. Carroll, B. J. (1983). Biologic markers and treatment response. Journal of Clinical Psychiatry, 44, 30–40.PubMedGoogle Scholar
  8. Charney, D. S., Heninger, G. R., Sternberg, D. E., Hafstad, K. M., Giddings, S., & Landis, D. H. (1982). Adrenergic receptor sensitivity in depression — Effects of Clonidine in depressed patients and healthy subjects. Archives of General Psychiatry, 39, 290–294.PubMedCrossRefGoogle Scholar
  9. Chouinard, G., Young, S. N., & Annable, L. (1983). Antimanic effect of clonazepam. Biological Psychiatry, 18, 451–466.PubMedGoogle Scholar
  10. Claycomb, J. B. (1978). Endogenous anxiety: Implications for nosology and treatment. Journal of Clinical Psychiatry, 44, 19–22.Google Scholar
  11. Colello, G. D., Hockenbery, D. M., Bosmann, H. B., Fuchs, S., & Folkers, K. (1978). Competitive inhibition of benzodiazepine binding by fractions from porcine brain. Proceedings of the National Academy of Science, 75, 6319–6323.CrossRefGoogle Scholar
  12. Cooper, A. J., & Datta, S. R. (1980). A placebo controlled evaluation of L-tryptophan in depression in the elderly. Canadian Journal of Psychiatry, 25, 386–390.Google Scholar
  13. Coppen, A. (1967). The biochemistry of affective disorders. British Journal of Psychiatry, 113, 1237–1264.PubMedCrossRefGoogle Scholar
  14. Costa, E., & Guidotti, A. (1979). Molecular mechanisms in the receptor action of benzodiazepines. Annual Review of Pharmacology and Toxicology, 19, 531–545.PubMedCrossRefGoogle Scholar
  15. de Montigny, C., Grunberg, F., Mayer, A., & Deschenes, J. P. (1981). Lithium induces rapid relief of depression in tricyclic antidepressant drug non-responders. British Journal of Psychiatry, 138, 252–256.PubMedCrossRefGoogle Scholar
  16. Drimmer, E. J., Gitlin, M. J., & Gwirtsman, H. E. (1983). Desipramine and methylphenidate combination treatment for depression: Case report. American Journal of Psychiatry, 140, 241–242.PubMedGoogle Scholar
  17. Emerson, T. R., Pare, C.M.B., Turner, P., & Hathaway, N. R. (1981). The use of a beta blocker (Acebutolol, “Sectral”) and a benzodiazepine (Diazepam) in the treatment of anxiety. Current Therapeutic Research, 29, 693–703.Google Scholar
  18. Fabre, L. F., & Napoliello, M. J. (1981). An open dose-finding study of melperone in nonpsychotic outpatients with anxiety. Current Therapeutic Research, 30, 427–433.Google Scholar
  19. Feighner, J. P. (1980). Pharmacology: New antidepressants. Psychiatric Annals, 10, 388–395.Google Scholar
  20. Feighner, J. P., Merideth, C. H., & Hendrickson, G. A. (1982). A double-blind comparison of buspirone and diazepam in outpatients with generalized anxiety disorder. Journal of Clinical Psychiatry, 43(12), (Sec. 2), 103–108.PubMedGoogle Scholar
  21. Fontaine, R., Annable, L., Chouinard, G., & Ogilvie, R. I. (1983). Bromazepam and diazepam in generalized anxiety: A placebo-controlled study with measurement of drug plasma concentrations. Journal of Clinical Psychopharmacology, 3(2), 80–87.PubMedCrossRefGoogle Scholar
  22. Friedmann, C. T. H., Davis, L. J., Ciccone, P. E., & Rubin, R. T. (1980). Phase II double-blind controlled study of a new anxiolytic, Fenobam (McN-3377) vs. placebo. Current Therapeutic Research, 27(2), 144–151.Google Scholar
  23. Garcia-Sevilla, J. A., Zis, A. P., Hollingsworth, P. J., Greden, J. F., & Smith, C. B. (1981). Platelet 2-adrenergic receptors in major depressive disorder — Binding of tritiated Clonidine before and after tricyclic antidepressant drug treatment. Archives of General Psychiatry, 38, 1327–1333.PubMedCrossRefGoogle Scholar
  24. Gelenberg, A. J., Wojcik, J. D., Gibson, C. J., & Wurtman, R. J. (1982). Tyrosine for depression. Journal of Psychiatric Research, 17, 175–180.PubMedCrossRefGoogle Scholar
  25. Gelenberg, A. J., Wojcik, J. D., Growdon, J. H., Sved, A. F., & Wurtman, R. J. (1980). Tyrosine for the treatment of depression. American Journal of Psychiatry, 137, 622–623.PubMedGoogle Scholar
  26. Goldberg, H. L., & Finnerty, R. (1982). Comparison of buspirone in two separate studies. Journal of Clinical Psychiatry, 43(12) (Sec. 2), 87–91.PubMedGoogle Scholar
  27. Goldberg, I. K. (1980). L-tyrosine in depression. The Lancet, 364.Google Scholar
  28. Goodwin, F. K., Prange, A. J., Jr., Post, R. M., Muscettola, G., & Lipton, M. A. (1982). Potentiation of antidepressant effects by L-triiodothyronine in tricyclic nonresponders. American Journal of Psychiatry, 139, 24–38.Google Scholar
  29. Greenblatt, D. J., Shader, R. I., Harmatz, J. S., Franke, K., & Koch-Weser, J. (1977). Absorption rate, blood concentrations, and early response to oral chlordiazepoxide. American Journal of Psychiatry, 134, 559–562.PubMedGoogle Scholar
  30. Haefely, W., Pole, P., Pieri, L., Schaffner, R., & Laurent, J. P. (1983). Neuropharmacology of benzodiazepines: Synaptic mechanisms and neural basis of action. In E. Costa (Ed.), The benzodiazepines: From molecular biology to clinical practice. New York: Raven Press.Google Scholar
  31. Itoh, H., Takahashi, R., & Miura, S. (1980). Alprazolam, a new type anxiolytic in neuroleptic patients — — A pilot study. International Pharmacopsychiatry, 15, 344–349.PubMedGoogle Scholar
  32. Janke, W., & Netter, P. (1983). Anxiolytic effects of drugs: Approaches, methods and problems. Neuropsychobiology, 9, 33–40.PubMedCrossRefGoogle Scholar
  33. Jimerson, D. C., Post, R. M., Stoddard, F. J., Gillin, J. C., & Bunney, W. E. (1980). Preliminary trial of the noradrenergic agonist Clonidine in psychiatric patients. Biological Psychiatry, 15, 45–57.PubMedGoogle Scholar
  34. Kaneko, M., Kumashiro, H., Takahashi, Y., & Hoshino, Y. (1979). L-5-HTP treatment and serum 5-HT level after L-5-HTP loading on depressed patients. Neuropsychobiology, 5, 232–240.PubMedCrossRefGoogle Scholar
  35. Kathol, R. G., Noyes, R. Jr., Slymen, D. J., Crowe, R. R., Clancy, J., & Kerber, R. E. (1980). Propranolol in chronic anxiety disorders — A controlled study. Archives of General Psychiatry, 37, 1361–1365.PubMedCrossRefGoogle Scholar
  36. Kelwala, S., Jones, D., & Sitaram, N. (1983). Monoamine metabolites as predictors of antidepressant response: A critique. Progress in Neuropsychopharmacology & Biological Psychiatry, 7, 229–240.CrossRefGoogle Scholar
  37. Klaiber, E. L., Broverman, D. M., Vogel, W., & Kobayashi, T. (1979). Estrogen therapy for severe persistent depression in women. Archives of General Psychiatry, 36, 550–554.PubMedCrossRefGoogle Scholar
  38. Klein, D. F. (1964). Delineation of two drug responsive anxiety syndromes. Psychopharmacologia, 5, 397–408.PubMedCrossRefGoogle Scholar
  39. Klein, D. F., Davis, J. M. (1969). Diagnosis and drug treatment of psychiatric disorders. Baltimore: Williams & Wilkins.Google Scholar
  40. Kolasa, K., Fusi, R., Garattini, S., Consolo, S., & Ladinsky, H. (1982). Neurochemical effects of buspirone, a novel psychotropic drug, on the central cholinergic system. Journal of Pharmacy and Pharmacology, 34, 314–317.PubMedCrossRefGoogle Scholar
  41. Lader, M. (1979). Anxiety reduction and sedation: Psychophysiological theory. British Journal of Clinical Pharmacology, 7, 99S-105S.Google Scholar
  42. Lader, M., & Petursson, H. (1981). Benzodiazepine derivatives — Side effects and dangers. Biological Psychiatry, 16, 1195–1201.PubMedGoogle Scholar
  43. Lader, M., & Petursson, H. (1983). Rational use of anxiolytic/sedative drugs. Drugs, 25, 514–528.PubMedCrossRefGoogle Scholar
  44. Langer, G., Aschauer, H., Koinig, G., Resch, F., & Schonbeck, G. (1983). The TSH-response to TRH: A possible predictor of outcome to antidepressant and neuroleptic treatment. Progress in Neuropsychopharmacology & Biological Psychiatry, 7, 335–342.CrossRefGoogle Scholar
  45. Lapierre, Y. D. (1983). New antidepressant drugs. Journal of Clinical Psychiatry, 44, 41–44.PubMedGoogle Scholar
  46. Lapierre, Y.D., & Oyewumi, L.K. (1982). Fenobam, another anxiolytic? Current Therapeutic Research, 31, 95–101.Google Scholar
  47. Leonard, B. E. (1980). Pharmacological properties of some “second generation” antidepressant drugs. Neuropharmacology, 19, 1175–1183.PubMedCrossRefGoogle Scholar
  48. Lloyd, K. J., Farley, I. J., Deck, J. H. N., et al., (1974). Serotonin and 5-hydroxyindoleacetic acid in discrete areas of the brainstem of suicide victims and control patients. Advances in Biochemistry & Psychopharmacology, 11, 387–397.Google Scholar
  49. Maas, J. W. (1975). Biogenic amines and depression: Biochemical and pharmacological separation of two types of depression. Archives of General Psychiatry, 32, 1357–1361.PubMedCrossRefGoogle Scholar
  50. Maas, J. W., Koslow, S. H., Katz, M. M., Bowden, C. L., Gibbons, R. L., Stokes, P. E., Robins, E., & Davis, J. M. (1984). Pretreatment neurotransmitter metabolite levels and response to tricyclic antidepressant drugs. American Journal of Psychiatry, 141, 1159–1171.PubMedGoogle Scholar
  51. Mann, J., Peselow, E. D., Snyderman, S., & Gershon, S. (1980). D-phenyla-lanine in endogenous depression. American Journal of Psychiatry, 137, 1611–1612.PubMedGoogle Scholar
  52. Meltzer, H. Y. (1983). The effect of buspirone on prolactin and growth hormone secretion in man. Archives of General Psychiatry, 40, 1099–1102.PubMedCrossRefGoogle Scholar
  53. Mendels, J. (1976). Lithium in the treatment of depression. American Journal of Psychiatry, 133(4), 373–378.PubMedGoogle Scholar
  54. Mohler, H., & Okada, T. (1977). Benzodiazepine receptor: Demonstration in the central nervous system. Science, 198, 849–851.PubMedCrossRefGoogle Scholar
  55. Mohler, H., Pole, P., Sumin, R., Pieri, L., & Kettler, R. (1979). Nicotinamide is a brain constituent with benzodiazepine-like actions. Nature, 278, 563–565.PubMedCrossRefGoogle Scholar
  56. Nies, A., Robinson, D. S., Bartlett, D., & Lambourn, M. R. (1977). M.A.O. inhibitors in clinical practice: Principles based on recent research. Psychopharmacological Bulletin, 13, 54–55.Google Scholar
  57. Oppenheim, G. (1983). Estrogen in the treatment of depression: Neuropharmacological mechanisms. Biological Psychiatry, 18, 721–725.PubMedGoogle Scholar
  58. Pare, C. M. B. (1979). Monoamine oxidase inhibitors in resistant depression. International Psychopharmacopsychiatry, 14, 101–109.Google Scholar
  59. Pecknold, J. C., McClure, D. J., & Appeltauer, L. (1980). Fenobam in anxious out-patients. Current Therapeutic Research, 27, 119–123.Google Scholar
  60. Peet, M., & Coppen, A. (1980). Lithium treatment and prophylaxis in unipolar depression. Psychosomatics, 21, 303–313.PubMedGoogle Scholar
  61. Prange, A. J., Wilson, I. C., Robon, A. M., & Lipton, M. (1969). Enhancement of imipramine antidepressant activity by thyroid hormone. American Journal of Psychiatry, 126, 457–469.PubMedGoogle Scholar
  62. Quitkin, F. M., Rabkin, J. G., Ross, D., & McGrath, P. J. (1984). Duration of antidepressant drug treatment — What is an adequate trial? Archives of General Psychiatry, 41, 238–245.PubMedCrossRefGoogle Scholar
  63. Ravaris, C. L., Robinson, D. S., Ives, J. O., Nies, A., & Bartlett, D. (1980). Phenelzine and amitriptyline in the treatment of depression — A comparison of present and past studies. Archives of General Psychiatry, 37, 1075–1080.PubMedCrossRefGoogle Scholar
  64. Sachar, E. J., Hellman, L., & Fukushima, D. K. (1970). Cortisol production in depressive illness. A clinical and biochemical clarification. Archives of General Psychiatry, 23, 289–298.PubMedCrossRefGoogle Scholar
  65. Schatzberg, A. F., Orsulak, P. J., Rosenbaum, A. H., Maruta, T., Kruger, E. R., Cole, J. O., & Schildkraut, J. J. (1982). Toward a biochemical classification of depressive disorders, V: Heterogeneity of unipolar depressions. American Journal of Psychiatry, 139, 471–475.PubMedGoogle Scholar
  66. Schildkraut, J. J. (1965). The catecholamine hypothesis of affective disorders: A review of supporting evidence. American Journal of Psychiatry, 122, 509–522.PubMedGoogle Scholar
  67. Seppala, T., Aranko, K., Mattila, M. J., & Shrotriya, R. C. (1982). Effects of alcohol on buspirone and lorazepam actions. Clinical Pharmacological Therapy, 32, 201–207.CrossRefGoogle Scholar
  68. Shader, R. I., & Greenblatt, P. J. (1977). Clinical implications of benzodiazepine pharmacokinetics. American Journal of Psychiatry, 134(6), 652–656.PubMedGoogle Scholar
  69. Sheehan, D. V. (1984). Delineation of anxiety and phobic disorders responsive to monoamine inhibitors: Implications for classification. Journal of Clinical Psychiatry, 45 (Sec. 2), 29–36.PubMedGoogle Scholar
  70. Sheehan, D. V., Ballenger, J., & Jacobsen, C. (1980). Treatment of endogenous anxiety with phobic, hysterical, and hypochondriacal symptoms. Archives of General Psychiatry, 37, 51–59.PubMedCrossRefGoogle Scholar
  71. Sheehan, D. V., Coleman, J. H., Greenblatt, D. J., Jones, K. J., Levine, P. H., Orsulak, P. J., Peterson, M., Schildkrant, J. J., Uzogara, E., & Watkins, D. (1984). Biochemical correlates of panic attacks with agoraphobia and their response to a new treatment. Journal of Clinical Psychopharmacology, 4, 66–75.PubMedCrossRefGoogle Scholar
  72. Sheehan, D. V., & Sheehan, K. H. (1982). The classification of anxiety and hysterical states. Part II. Toward a more heuristic classification. Journal of Clinical Psychopharmacology, 2, 386–393.PubMedGoogle Scholar
  73. Shopsin, B., & Waters, B. (1980). The pharmacotherapy of major depressive syndrome. Part I: Treatment of acute depression. Psychosomatics, 21, 542–556.PubMedGoogle Scholar
  74. Smith, C. B., Hollingsworth, P. J., Garcia-Sevilla, J. A., & Zis, A. P. (1983). Platelet alpha2 adrenoreceptors are decreased in number after antidepressant therapy. Progress in Neuropsycho-pharmacology & Biological Psychiatry, 7, 241–247.CrossRefGoogle Scholar
  75. Spitzer, R. L., & Williams, J. B. W. (1982). Hysteroid Dysphoria: An unsuccessful attempt to demonstrate its syndromal validity. American Journal of Psychiatry, 139(10), 1286–1291.PubMedGoogle Scholar
  76. Sulser, F. (1983). Deamplification of noradrenergic signal transfer by antidepressants: A unified catecholamine-serotonin hypothesis of affective disorders. Psychopharmacological Bulletin, 19, 300–304.Google Scholar
  77. Targum, S. D. (1983). The application of serial neuroendocrine challenge studies in the management of depressive disorder. Biological Psychiatry, 18, 3–19.PubMedGoogle Scholar
  78. Taylor, D. P., Riblet, L. A., Stanton, H. C., Eison, A. S., Eison, M. S., Temple, D. L. Jr. (1982). Dopamine and antianxiety activity. Pharmacological & Biochemical Behavior, 17, 25–35.CrossRefGoogle Scholar
  79. Tyrer, P. J., & Lader, M. H. (1974). Physiological response to propranolol and diazepam in chronic anxiety. British Journal of Clinical Pharmacology, 1, 387–390.Google Scholar
  80. Van Hiele, L. J. (1980). 5-hydroxytryptophan in depression: The first substitution therapy in psychiatry? Neuropsychobiology, 6, 230–240.PubMedCrossRefGoogle Scholar
  81. Van Praag, H. M. (1980). Central monoamine metabolism in depressions. II. Catecholamines and related compounds. Comprehensive Psychiatry, 21, 44–54.PubMedCrossRefGoogle Scholar
  82. Wharton, R. N., Perei, J. M., Dayton, P. G., & Malitz, S. (1971). A potential clinical use for methylphenidate (Ritalin) with tricyclic antidepressants. American Journal of Psychiatry, 127, 1619–1625.PubMedGoogle Scholar

Copyright information

© Plenum Press, New York 1986

Authors and Affiliations

  • Y. D. Lapierre
    • 1
  1. 1.University of OttawaCanada

Personalised recommendations